Print Page     Close Window     

SEC Filings

10-K
SERES THERAPEUTICS, INC. filed this Form 10-K on 03/06/2019
Entire Document
 

 

SERES THERAPEUTICS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

 

 

 

Year Ended December 31,

 

 

 

2018

 

 

2017

 

 

2016

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(98,942

)

 

$

(89,380

)

 

$

(91,579

)

Adjustments to reconcile net loss to net cash provided by (used in)

   operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation expense

 

 

16,641

 

 

 

17,362

 

 

 

16,857

 

Depreciation and amortization expense

 

 

7,862

 

 

 

7,259

 

 

 

4,205

 

Non-cash interest expense

 

 

 

 

 

3

 

 

 

 

Accretion of discount on investments

 

 

(214

)

 

 

(216

)

 

 

(386

)

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Prepaid expenses and other current assets

 

 

(2,056

)

 

 

31

 

 

 

(2,598

)

Deferred revenue

 

 

13,476

 

 

 

(11,888

)

 

 

108,814

 

Accounts payable

 

 

(353

)

 

 

(856

)

 

 

3,581

 

Accrued expenses and other liabilities

 

 

732

 

 

 

2,162

 

 

 

5,027

 

Net cash provided by (used in) operating activities

 

 

(62,854

)

 

 

(75,523

)

 

 

43,921

 

Cash flows from investing activities:

 

 

 

 

 

 

 

 

 

 

 

 

Purchases of property and equipment

 

 

(1,937

)

 

 

(4,676

)

 

 

(21,492

)

Purchases of investments

 

 

(21,832

)

 

 

(97,934

)

 

 

(290,594

)

Sales and maturities of investments

 

 

136,087

 

 

 

158,312

 

 

 

246,494

 

Net cash provided by (used in) investing activities

 

 

112,318

 

 

 

55,702

 

 

 

(65,592

)

Cash flows from financing activities:

 

 

 

 

 

 

 

 

 

 

 

 

Proceeds from exercise of stock options

 

 

147

 

 

 

116

 

 

 

2,138

 

Proceeds from issuance of common stock and restricted common stock

 

 

61

 

 

 

 

 

 

 

Payments for repurchase of common stock for employee tax withholdings

 

 

(197

)

 

 

(33

)

 

 

 

Issuance of common stock under ESPP plan

 

 

257

 

 

 

 

 

 

 

Net cash provided by financing activities

 

 

268

 

 

 

83

 

 

 

2,138

 

Net increase (decrease) in cash, cash equivalents and restricted cash

 

 

49,732

 

 

 

(19,738

)

 

 

(19,533

)

Cash, cash equivalents and restricted cash at beginning of year

 

 

36,201

 

 

 

55,939

 

 

 

75,472

 

Cash, cash equivalents and restricted cash at end of year

 

$

85,933

 

 

$

36,201

 

 

$

55,939

 

Supplemental disclosure of cash flow information:

 

 

 

 

 

 

 

 

 

 

 

 

Cash paid for interest

 

$

 

 

$

1

 

 

$

109

 

Supplemental disclosure of non-cash investing and financing

   activities:

 

 

 

 

 

 

 

 

 

 

 

 

Property and equipment purchases included in accounts payable and

   accrued expenses

 

$

157

 

 

$

877

 

 

$

1,650

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

 

F-6



© Seres Therapeutics. All Rights Reserved.